Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily.
about
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaDasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.Spotlight on dasatinib in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemiaThe role of dasatinib in the management of chronic myeloid leukemiaThe transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells.Differential effects of procaspase-3 activating compounds in the induction of cancer cell death.Dasatinib-induced pleural effusion: Chylothorax, an option to consider.Current management of chronic myeloid leukemia with tyrosine kinase inhibitors.Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.Treatment of chronic myeloid leukemia when imatinib fails.The potential for dasatinib in treating chronic lymphocytic leukemia, acute myeloid leukemia, and myeloproliferative neoplasms.Selection of therapy: rational decisions based on molecular events.Evolution of therapies for chronic myelogenous leukemia.Treatments for chronic myeloid leukemia: a qualitative systematic review.Dasatinib for the treatment of Philadelphia chromosome-positive leukemias.Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization.Surrogate end points for long-term outcomes in chronic myeloid leukemia.Dasatinib: a guide to its use in chronic myeloid leukemia in the EU.Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients.Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia.A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase.BCR-ABL inhibitors: updates in the management of patients with chronic-phase chronic myeloid leukemia.Management of chronic myeloid leukemia in blast crisis.Management of advanced-phase chronic myeloid leukemia.Implementing the EffTox dose-finding design in the Matchpoint trial.New Methodologies in the Molecular Monitoring of CML.Second line small molecule therapy options for treating chronic myeloid leukemia.Monitoring disease burden in chronic myeloid leukemia: Past, present, and future.Molecular monitoring of chronic myeloid leukemia: present and future.How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety.Dasatinib: A Review in Chronic Myeloid Leukaemia and Ph+ Acute Lymphoblastic Leukaemia.Dasatinib for the treatment of chronic myeloid leukemia.Very long survival in complete cytogenetic remission in an adolescent with lymphoid blast crisis of chronic myeloid leukemia after treatment with intensive ALL-directed chemotherapy combined with continuous imatinib.Ponatinib as a Valid Alternative Strategy in Patients with Blast Crisis-Chronic Myeloid Leukemia Not Eligible for Allogeneic Stem Cells Transplantation and/or Conventional Chemotherapy: Report of a Case.Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation.Sequential Use of Second-Generation Tyrosine Kinase Inhibitor Treatment and Intensive Chemotherapy Induced Long-Term Complete Molecular Response in Imatinib-Resistant CML Patient Presenting as a Myeloid Blast Crisis.Isolated central nervous system relapse in patient with blast-crisis chronic myeloid leukemia in durable complete cytogenetic remission on dasatinib treatment: pharmacokinetics and ABL mutation analysis in cerebrospinal fluid.Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia.
P2860
Q26749324-49EB841A-B44B-4967-AD5D-0AF69D3B03FEQ33397085-930AFA82-B12F-4277-ADC9-FCBFBE56F305Q33399101-BCE6B76F-0B92-4682-B97E-0DC1970A9B39Q34522789-70B45655-7A09-4F26-BAC8-FB09EA5D9074Q35087994-4FA52356-1ECF-4D7D-A695-D3248D5FEC4FQ35608944-E36887C4-6B46-45D2-96F2-3B20BD19F32CQ35946431-D894011B-2BF9-4C6C-BEFD-2B12CF708E83Q37350583-6948D352-3D7D-47FE-AE72-E8FE16C43BA1Q37426573-69144C28-7F01-4FBF-91E9-6E4AAE2C0AC2Q37461942-DB2F5233-C0CA-4C88-BE38-5BC36119AF84Q37827875-3475C12F-5582-4357-A894-67961D8DDDE6Q37861186-C28E5015-F887-4A70-9B4F-DCBB4C98E701Q37952910-3E19ACA2-5C38-498A-8D0F-8BCDA427021FQ37966915-E9544572-A6BF-4B24-BBCE-C0285FA1B45AQ38037079-54779B9E-7AE8-42EB-89ED-1218016E7778Q38044753-F1E142FE-8A27-4147-B851-D8CAAC8E2099Q38067464-49B9CA7C-595E-4A1D-86A5-F6AF5477513EQ38079249-6A46CD1A-8632-4D68-84EB-F518F13D6786Q38095386-604599F8-5A2B-4B51-ABB2-C1CE2DBD5376Q38095848-5593BC63-E2D5-4CED-B072-622E17005FF0Q38128723-9A30EDE0-D417-4CE2-82DD-42C8E0635ACEQ38139571-73898DC8-D99D-40DE-B03F-A47CEF18F173Q38149613-62D40FD6-A00B-48B3-A78C-C7C267F099FAQ38154292-B422C999-E204-46EA-8DBF-DECAECAB0CCBQ38392682-31B36B48-2135-40BE-9B13-2ED4058C79EDQ38452040-D6BCCD76-8C73-4445-AEE2-DA3710B48E16Q38654251-C99E33EB-7C31-4695-9DF6-1A98220A6143Q38762203-8DFAC18D-168C-4A28-AEA2-0A386B4E5C16Q38789049-478D1F9D-185A-463D-AD97-E2E024F5F19DQ38802249-859E89EF-9CEC-4190-8156-85513D89B1DAQ38828713-327FE9D9-8259-4E6C-8DAF-C8306EFC70F7Q38845834-DF6452FC-1AE1-43FA-A3CE-AEFAC4E20685Q39061903-9141BA59-260D-4BA1-95B6-C559DDD6F20BQ39739850-211088CF-B00F-4A11-8D0E-3E904271A0E5Q40533806-79792110-0401-4B60-A430-C739DC01AF9CQ41613498-10149DFB-2E00-4599-9B9A-5022ECF699A9Q42615766-F8C1B776-CAAA-4F92-980E-A83E8D3124ECQ48119645-C7FFA656-3D6C-4806-A2C8-4499FE257A64Q48274819-0B549107-1C96-4D8F-B7F0-D8163255ECD2Q49593223-B23F11ED-C231-4525-B387-F82B0328A812
P2860
Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Dasatinib in imatinib-resistan ...... and 70 milligrams twice daily.
@en
Dasatinib in imatinib-resistan ...... and 70 milligrams twice daily.
@nl
type
label
Dasatinib in imatinib-resistan ...... and 70 milligrams twice daily.
@en
Dasatinib in imatinib-resistan ...... and 70 milligrams twice daily.
@nl
prefLabel
Dasatinib in imatinib-resistan ...... and 70 milligrams twice daily.
@en
Dasatinib in imatinib-resistan ...... and 70 milligrams twice daily.
@nl
P2093
P2860
P50
P356
P1433
P1476
Dasatinib in imatinib-resistan ...... and 70 milligrams twice daily.
@en
P2093
Frederic Maloisel
M Brigid Bradley-Garelik
Philipp Erben
Ricardo Pasquini
Ronald Paquette
Yeow Tee Goh
P2860
P304
P356
10.1002/CNCR.25123
P407
P577
2010-08-01T00:00:00Z